7504 Background: Poor performance status (PS) NSCLC is an important, under-studied
group of lung cancer patients, affecting 30-40% of patients. We determined the role of …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Background: A randomized trial carried out by Shepherd et al. in patients with advanced or
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …

19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …

Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

7073 Background: Erlotinib (TarcevaTM) is an orally available selective EGFR tyrosine-
kinase inhibitor. In patients with advanced NSCLC, 2nd/3rd-line erlotinib significantly …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …